Working to facilitate rapid translation of scientific discoveries into therapeutics

Sinisa Dovat

Schmidt_cutted-1

Sinisa Dovat

Dr. Dovat completed his clinical training in Pediatrics in Penn State University, and in Pediatric Hematology/Oncology at UCLA-Children’s Hospital. He received his research training at Cornell University Graduate School of Medical Sciences and at Howard Hughes Medical Institute at UCLA. During his postdoctoral training at UCLA, Dr. Dovat began his research on the role of Ikaros family genes in normal hematopoiesis and in leukemia. As an independent investigator at the University of Wisconsin, Dr. Dovat focused his work on the regulation of the tumor suppressor activity of Ikaros in childhood leukemia. Results of his research led to the discovery that CK2 kinase negatively regulates the tumor suppressor activity of Ikaros in leukemia and identified three signal transduction pathways that control Ikaros function: CK2 kinase, Protein Phosphatase 1 (PP1), and ubiquitination, These data provided a mechanistic basis for the use of CK2 inhibitors for treatment of hematological malignancies. Dr. Dovat is the recipient of The Young Investigator Award by The American Society of Pediatric Hematology/Oncology, and has been included in the Best Doctors in America list since 2008. His research is supported by a National Institute of Health (NIH) R01 grant and several philanthropic foundations. Dr. Dovat accepted the position of Four Diamond Endowed Chair and Director of Translational Research and Experimental Therapeutics in Pediatric Hematology/Oncology at Penn State University beginning in September, 2010, Concurrently, Dr. Dovat is studying epigenomic regulation of cellular immortalization and senescence in leukemia.

2013-2021©European Society for Translational Medicine (EUSTM)